With doubts about voucher program extension, Acadia strikes $150M sale

The $150 million price tag in Acadia’s sale of a priority review voucher is among the largest in years, suggesting doubts about the reauthorization of FDA’s pediatric voucher program are driving up the vouchers’ cost.

For years, the price of the transferable vouchers had hovered around $100 million. One other transaction in the past few months, an August sale of a voucher by Ipsen Group (Euronext:IPN; Pink:IPSEY), came in substantially higher at $158 million...